See more : Nostra Terra Oil and Gas Company plc (NTOG.L) Income Statement Analysis – Financial Results
Complete financial analysis of AIkido Pharma Inc. (AIKI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AIkido Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Smiths Group plc (SMGZY) Income Statement Analysis – Financial Results
- Central Depository Services (India) Limited (CDSL.NS) Income Statement Analysis – Financial Results
- Wilson Learning Worldwide Inc. (9610.T) Income Statement Analysis – Financial Results
- GE HealthCare Technologies Inc. (GEHC) Income Statement Analysis – Financial Results
- Meiwa Corporation (8103.T) Income Statement Analysis – Financial Results
AIkido Pharma Inc. (AIKI)
About AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 9.00K | 28.00K | 1.24M | 877.00K | 33.00K | 10.00K | 27.00K | 19.92K | 820.93K | 1.43M | 1.36M | 1.03M | 154.70K | 24.84M | 23.05M | 22.35M | 18.09M | 15.13M | 19.94M | 17.03M | 12.70M | 16.00M | 13.60M | 13.80M | 13.70M | 16.00M | 13.60M | 16.70M | 15.10M | 15.90M | 15.30M | 13.60M | 10.50M | 8.00M | 6.70M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 81.00K | 92.00K | 84.00K | 88.00K | 864.00K | 3.00K | 0.00 | 388.07K | 517.68K | 449.29K | 397.65K | 54.29K | 20.79M | 17.93M | 17.36M | 12.60M | 11.55M | 13.64M | 11.09M | 9.60M | 12.50M | 9.90M | 9.60M | 9.90M | 12.90M | 10.40M | 13.20M | 12.40M | 13.30M | 12.90M | 11.10M | 7.70M | 5.90M | 5.20M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 9.00K | -53.00K | 1.14M | 793.00K | -55.00K | -854.00K | 24.00K | 19.92K | 432.86K | 914.78K | 909.82K | 628.32K | 100.41K | 4.04M | 5.12M | 4.99M | 5.48M | 3.58M | 6.30M | 5.95M | 3.10M | 3.50M | 3.70M | 4.20M | 3.80M | 3.10M | 3.20M | 3.50M | 2.70M | 2.60M | 2.40M | 2.50M | 2.80M | 2.10M | 1.50M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | -189.29% | 92.56% | 90.42% | -166.67% | -8,540.00% | 88.89% | 100.00% | 52.73% | 63.86% | 66.94% | 61.24% | 64.90% | 16.28% | 22.21% | 22.31% | 30.32% | 23.66% | 31.59% | 34.91% | 24.41% | 21.88% | 27.21% | 30.43% | 27.74% | 19.38% | 23.53% | 20.96% | 17.88% | 16.35% | 15.69% | 18.38% | 26.67% | 26.25% | 22.39% |
| Research & Development | 830.00K | 559.00K | 2.49M | 2.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 727.09K | 1.65M | 4.85M | 6.83M | 4.00M | 5.87M | 883.61K | 288.11K | 196.36K | 423.17K | 476.00K | 390.16K | 281.08K | 300.00K | 400.00K | 600.00K | 600.00K | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.68M | 7.73M | 4.06M | 0.00 | 3.06M | 3.69M | 4.58M | 5.13M | 20.79M | 15.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.68M | 7.73M | 4.06M | 3.17M | 3.06M | 3.69M | 4.58M | 5.13M | 20.79M | 15.07M | 2.76M | 3.13M | 4.08M | 3.27M | 3.14M | 3.87M | 5.64M | 5.14M | 5.36M | 5.83M | 4.51M | 4.03M | 3.94M | 3.70M | 3.80M | 2.80M | 2.50M | 2.30M | 2.70M | 2.00M | 1.90M | 2.10M | 2.30M | 2.30M | 1.60M | 1.30M | 1.20M | 1.10M |
| Other Expenses | 1.83M | 1.15M | 1.47M | 0.00 | 1.44M | 1.37M | 2.14M | 6.32M | 9.83M | 291.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57M | 2.28M | 1.50M | 1.59M | 1.42M | 1.31M | 1.70M | 1.30M | 600.00K | 700.00K | 500.00K | 400.00K | 500.00K | 600.00K | 600.00K | 600.00K | 500.00K | 500.00K | 400.00K | 300.00K | 200.00K |
| Operating Expenses | 14.35M | 9.44M | 6.55M | 5.69M | 4.50M | 5.06M | 6.72M | 11.44M | 30.62M | 15.37M | 3.49M | 4.78M | 8.93M | 10.10M | 7.14M | 9.74M | 6.52M | 8.00M | 7.83M | 7.76M | 6.58M | 5.84M | 5.54M | 5.70M | 5.50M | 4.00M | 3.80M | 3.30M | 3.10M | 2.50M | 2.50M | 2.70M | 2.90M | 2.80M | 2.10M | 1.70M | 1.50M | 1.30M |
| Cost & Expenses | 14.35M | 9.44M | 6.55M | 5.69M | 4.50M | 5.06M | 6.72M | 11.44M | 30.62M | 15.37M | 3.49M | 5.17M | 9.44M | 10.55M | 7.54M | 9.79M | 27.32M | 25.93M | 25.19M | 20.36M | 18.13M | 19.48M | 16.62M | 15.30M | 18.00M | 13.90M | 13.40M | 13.20M | 16.00M | 12.90M | 15.70M | 15.10M | 16.20M | 15.70M | 13.20M | 9.40M | 7.40M | 6.50M |
| Interest Income | 687.00K | 252.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.46K | 6.11K | 37.65K | 348.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.76M | -2.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.00K | 2.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -188.00K | 2.27M | -5.79M | 1.50M | 1.44M | 1.38M | 2.14M | 6.32M | 9.83M | 291.00K | 63.68K | 69.83K | 77.87K | 84.38K | 85.72K | 210.42K | 2.60M | 2.57M | 2.28M | 1.50M | 1.59M | 1.42M | 1.31M | 1.70M | 1.30M | 600.00K | 700.00K | 500.00K | 400.00K | 500.00K | 600.00K | 600.00K | 600.00K | 500.00K | 500.00K | 400.00K | 300.00K | 200.00K |
| EBITDA | -14.35M | -7.17M | -12.34M | -4.18M | 3.17M | -1.93M | -4.34M | -45.15M | -20.70M | -17.67M | -3.79M | -3.38M | -7.79M | -9.06M | -4.60M | -4.14M | 6.22M | -274.50K | -544.36K | -753.77K | -1.33M | 1.99M | 1.91M | -3.20M | -800.00K | 400.00K | 900.00K | 1.00M | 400.00K | -100.00K | 1.70M | 800.00K | 300.00K | 100.00K | 800.00K | 1.30M | 800.00K | 300.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 11,321.43% | -156.15% | -494.64% | -136,809.09% | -207,010.00% | -65,459.26% | -19,041.00% | -411.41% | -543.93% | -666.93% | -448.40% | -2,673.58% | 25.04% | -1.19% | -2.44% | -4.17% | -8.78% | 9.99% | 11.19% | -25.20% | -5.00% | 2.94% | 6.52% | 7.30% | 2.50% | -0.74% | 10.18% | 5.30% | 1.89% | 0.65% | 5.88% | 12.38% | 10.00% | 4.48% |
| Operating Income | -14.35M | -9.44M | -6.55M | -5.69M | -6.87M | -3.82M | -8.55M | -52.01M | -30.61M | -15.35M | -3.47M | -4.35M | -8.01M | -9.19M | -6.51M | -9.64M | -2.48M | -2.89M | -2.85M | -2.27M | -3.00M | 453.77K | 411.05K | -2.60M | -2.00M | -300.00K | 400.00K | 500.00K | 0.00 | 700.00K | 1.00M | 200.00K | -300.00K | -400.00K | 400.00K | 1.10M | 600.00K | 200.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -63,166.67% | -24,550.00% | -309.22% | -975.03% | -157,606.06% | -306,110.00% | -56,840.74% | -17,427.99% | -529.51% | -559.28% | -675.90% | -634.68% | -6,229.60% | -9.98% | -12.52% | -12.73% | -12.58% | -19.85% | 2.28% | 2.41% | -20.47% | -12.50% | -2.21% | 2.90% | 3.65% | 0.00% | 5.15% | 5.99% | 1.32% | -1.89% | -2.61% | 2.94% | 10.48% | 7.50% | 2.99% |
| Total Other Income/Expenses | -7.76M | 2.27M | -5.79M | 1.50M | 8.60M | 516.00K | 2.08M | 545.00K | 79.00K | -2.62M | 583.97K | 899.72K | 142.02K | 37.65K | 340.23K | 377.98K | 6.10M | 37.15K | 23.45K | 17.88K | 81.07K | 114.06K | 0.00 | -2.30M | -100.00K | 100.00K | -200.00K | 0.00 | 0.00 | -100.00K | 100.00K | 0.00 | -300.00K | -100.00K | -100.00K | -200.00K | -100.00K | 0.00 |
| Income Before Tax | -22.11M | -7.17M | -12.34M | -4.18M | 1.73M | -3.31M | -6.48M | -51.47M | -30.53M | -17.97M | -2.89M | -3.45M | -7.87M | -9.15M | -6.17M | -9.26M | 3.62M | -2.85M | -2.82M | -2.26M | -2.92M | 567.82K | 0.00 | -4.90M | -2.10M | -200.00K | 200.00K | 500.00K | 0.00 | 600.00K | 1.10M | 200.00K | -600.00K | -500.00K | 300.00K | 900.00K | 500.00K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 6,167.86% | -267.48% | -738.43% | -155,954.55% | -305,320.00% | -66,537.04% | -14,496.70% | -419.91% | -549.37% | -673.13% | -601.52% | -5,985.26% | 14.57% | -12.36% | -12.63% | -12.48% | -19.31% | 2.85% | 0.00% | -38.58% | -13.13% | -1.47% | 1.45% | 3.65% | 0.00% | 4.41% | 6.59% | 1.32% | -3.77% | -3.27% | 2.21% | 8.57% | 6.25% | 0.00% |
| Income Tax Expense | 7.76M | -2.27M | 0.00 | 0.00 | 8.60M | 516.00K | 2.08M | 545.00K | 79.00K | -2.62M | 583.97K | 14.49K | -133.19K | 37.65K | -552.80K | -3.41M | 105.05K | 37.15K | 23.45K | 17.88K | 81.12K | 114.06K | 0.00 | 300.00K | -100.00K | -100.00K | 100.00K | 100.00K | 100.00K | 200.00K | 400.00K | 100.00K | -200.00K | -200.00K | 100.00K | 400.00K | 200.00K | 0.00 |
| Net Income | -29.87M | -4.90M | -12.34M | -4.18M | 1.73M | -3.31M | -6.48M | -51.47M | -30.53M | -17.97M | -3.86M | -3.46M | -7.74M | -9.15M | -4.14M | -938.37K | 3.51M | -2.85M | -2.82M | -2.26M | -2.92M | 567.82K | 591.07K | -5.20M | -2.00M | -100.00K | 100.00K | 400.00K | -100.00K | -800.00K | 700.00K | 100.00K | -400.00K | -300.00K | 200.00K | 500.00K | 300.00K | 100.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 6,167.86% | -267.48% | -738.43% | -155,954.55% | -305,320.00% | -66,537.04% | -19,360.63% | -421.68% | -540.07% | -673.13% | -403.09% | -606.58% | 14.14% | -12.36% | -12.63% | -12.48% | -19.31% | 2.85% | 3.47% | -40.94% | -12.50% | -0.74% | 0.72% | 2.92% | -0.63% | -5.88% | 4.19% | 0.66% | -2.52% | -1.96% | 1.47% | 4.76% | 3.75% | 1.49% |
| EPS | -5.60 | -2.97 | -7.47 | -28.31 | 15.48 | -43.13 | -126.45 | -2.20K | -2.12K | -18.73K | -19.38K | -36.06K | -117.22K | -147.56K | -79.53K | -18.05K | 70.26K | -63.31K | -64.14K | -53.73K | -71.27K | 14.56K | 15.16K | -148.57K | -60.61K | -3.13K | 3.45K | 13.79K | -3.57K | -28.57K | 25.00K | 3.57K | -14.29K | -10.71K | 7.14K | 17.86K | 10.71K | 3.57K |
| EPS Diluted | -5.60 | -2.97 | -7.47 | -28.31 | 15.48 | -43.13 | -121.90 | -2.20K | -2.12K | -18.73K | -19.38K | -36.06K | -117.22K | -147.56K | -79.53K | -18.05K | 70.26K | -63.31K | -64.14K | -53.73K | -71.27K | 14.56K | 15.16K | -148.57K | -60.61K | -3.13K | 3.45K | 13.79K | -3.57K | -28.57K | 25.00K | 3.57K | -14.29K | -10.71K | 7.14K | 17.86K | 10.71K | 3.57K |
| Weighted Avg Shares Out | 5.33M | 1.65M | 1.65M | 147.74K | 111.57K | 76.66K | 51.21K | 23.44K | 14.38K | 959.00 | 199.00 | 96.00 | 66.00 | 62.00 | 52.00 | 52.00 | 50.00 | 45.00 | 44.00 | 42.00 | 41.00 | 39.00 | 39.00 | 35.00 | 33.00 | 32.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 |
| Weighted Avg Shares Out (Dil) | 5.33M | 1.65M | 1.65M | 147.74K | 111.57K | 76.66K | 53.13K | 23.44K | 14.38K | 959.00 | 199.00 | 96.00 | 66.00 | 62.00 | 52.00 | 52.00 | 50.00 | 45.00 | 44.00 | 42.00 | 41.00 | 39.00 | 39.00 | 35.00 | 33.00 | 32.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 |
5 Penny Stocks To Watch Under $1 After CEI Stock's 900% Rally
Best penny stocks to watch under $1? The post 5 Penny Stocks To Watch Under $1 After CEI Stock's 900% Rally appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AIkido Pharma Secures Interest in Electric Truck Maker, Tevva Motors Ltd
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company secured an equity interest in Tevva Motors Ltd, an electric truck producer with range extended vehicles on the road now.
Are Biotech Penny Stocks Worth Buying? Check These 3 Out
Biotech penny stocks are heating up right now, here's three to watch The post Are Biotech Penny Stocks Worth Buying? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AIkido Pharma Secures Interest in Growing Tele-health Company
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company secured an early equity interest in tele-health company, Kerna Health (https://kernahealth.com).
AIkido Provides Update on Use of Machine Learning in Drug Development Program
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided and update on the use of Machine Learning in support of its antiviral platform with the University of Maryland Baltimore School of...
Notice of Allowance Issued for Central Nervous System Peptide Technology
NEW YORK, July 27, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/477,125.
AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland
NEW YORK, July 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update to the progress of its antiviral platform with the University of Maryland School of Medicine. The Company stated: The goal for...
AIkido Pharma to Attend the Alzheimer's Association International Conference
NEW YORK, July 13, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced it will attend the Alzheimer's Association International Conference in Denver, July 26-30, 2021. ("AAIC 2021") The AAIC is the largest and most influential international meeting dedicated...
AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease
NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease. The Company previously secured...
AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591
NEW YORK, June 4, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4, 2021. The poster presentation of the...
Source: https://incomestatements.info
Category: Stock Reports